Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa

International Journal of Eating Disorders

Volumn 45, Issue 2, 2012, Pages 263-271

  Bailer, Ursula F ^a,b   Narendran, Rajesh ^c   Frankle, W Gordon ^c   Himes, Michael L ^c   Duvvuri, Vikas ^b   Mathis, Chester A ^c   Kaye, Walter H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

ampheta mine; anorexia nervosa; anxiety; dopamine; positron emission tomography

Indexed keywords

AMPHETAMINE; RACLOPRIDE C 11;

ANOREXIA NERVOSA; ANXIETY; ARTICLE; BEHAVIOR; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG BINDING; DRUG BLOOD LEVEL; EUPHORIA; FEMALE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AMPHETAMINE; ANOREXIA NERVOSA; ANXIETY; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; EUPHORIA; FEMALE; HUMANS;

EID: 84857056948     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.20937     Document Type: Article

References (62)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
2. Kendler KS, MacLean C, Neale M, Kessler R, Heath A, Eaves L,. The genetic epidemiology of bulimia nervosa. Am J Psychiatry 1991; 148: 1627-1637.
3. Berrettini W,. Genetics of psychiatric disease. Annu Rev Med 2000; 51: 465-479. (Pubitemid 30216050)
4. Bulik C, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL,. Prevalence, heritability and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry 2006; 63: 305-312. (Pubitemid 43345355)
5. Wagner A, Barbarich N, Frank G, Bailer U, Weissfeld L, Henry S, et al. Personality traits after recovery from eating disorders: Do subtypes differ? Int J Eat Disord 2006; 39: 276-284.
6. Klump K, Strober M, Johnson C, Thornton L, Bulik C, Devlin B, et al. Personality characteristics of women before and after recovery from an eating disorder. Psych Med 2004; 34: 1407-1418. (Pubitemid 39599939)
7. Lilenfeld L, Wonderlich S, Riso LP, Crosby R, Mitchell J,. Eating disorders and personality: A methodological and empirical review. Clin Psychol Rev 2006; 26: 299-320.
8. Bulik C, Tozzi F, Anderson C, Mazzeo S, Aggen S, Sullivan P,. The relation between eating disorders and components of perfectionism. Am J Psychiatry 2003; 160: 366-368. (Pubitemid 41110465)
9. Kaye W,. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94: 121-135. (Pubitemid 351506510)
10. Halford J, Cooper G, Dovey T,. The pharmacology of human appetite expression. Curr Drug Targets 2004; 5: 221-240. (Pubitemid 38372309)
11. Volkow ND, Wang G, Fowler J, Logan j, Jayne M, Franceschi D, et al. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylephenidate amplifies this effect. Synapse 2002; 44: 175-180. (Pubitemid 34303915)
12. Bergen A, Yeager M, Welch R, Haque K, Ganjei JK, Mazzanti C, et al. Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharm 2005; 30: 1703-1710. (Pubitemid 43086027)
13. Lawrence A,. Impaired visual discrimination learning in anorexia nervosa. Appetite 2003; 20: 85-89. (Pubitemid 36288467)
14. Friederich HC, Kumari V, Uher R, Riga M, Schmidt U, Campbell IC, et al. Differential motivational responses to food and pleasurable cues in anorexia and bulimia nervosa: A startle reflex paradigm. Psychol Med 2006; 36: 1327-1335. (Pubitemid 44184710)
15. Kaye WH, Frank GK, McConaha C,. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharm 1999; 21: 503-506. (Pubitemid 29414794)
16. 11C]raclopride. Biol Psychiatry 2005; 58: 908-912. (Pubitemid 41790720)
17. Bailer UF, Frank GK, Price JC, Meltzer CC, Becker CR,Mathis CA, Wagner A, et al. Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa (submitted).
18. Delgado M, Nystrom L, Fissel C, Noll D, Fiez J,. Tracking the hemodynamic responses to reward and punishment in the striatum. J Neurophysiol 2000; 84: 3072-3077.
19. Montague R, Hyman S, Cohen J,. Computational roles for dopamine in behavioural control. Nature 2004; 431: 760-767. (Pubitemid 39434064)
20. Schultz W,. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Science 2004; 14: 139-147. (Pubitemid 38479929)
21. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574. (Pubitemid 27136916)
22. Laruelle M, Iyer R, Al-Tikriti M, Zea-Ponce Y, Malison R, Zoghbi S,. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25: 1-14. (Pubitemid 27014356)
23. Martinez D, Gil R, Slifstein M, Hwang D, Huang Y, Perez A, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005; 58: 779-786. (Pubitemid 41677416)
24. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang D, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300. (Pubitemid 36307573)
25. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002; 52: 896-906. (Pubitemid 35223433)
26. 2A receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004; 29: 1143-1155. (Pubitemid 38670051)
27. 11C]WAY100635. Arch Gen Psychiatry 2005; 62: 1032-1041. (Pubitemid 41248383)
28. 2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry 2007; 61: 1090-1099. (Pubitemid 46551971)
29. Bailer UF, Frank G, Henry S, Price J, Meltzer CC, Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007; 195: 315-324.
30. Halldin C, Farde L, Hogberg T, Hall H, Strom P, Solin O,. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int J Rad App Instrum B. 1991; 18: 871-881.
31. Innis R, Cunningham V, Delforge J, Fujita M, Gjedde A, Gunn R, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539. (Pubitemid 47301451)
32. Narendran R, Frankle W, Mason N, Laymon C, Lopresti B, Price C, et al. Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [C]-N-propyl-norapomorphine: Preliminary evaluation and reproducibility studies. Synapse. 2009; 63: 574-584.
33. Narendran R, Mason N, Laymon C, Lopresti B, Velasquez N, May M, et al. A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010; 333: 533-539.
34. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang D, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034-1057. (Pubitemid 32823740)
35. 18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharm 2005; 31: 1016-1026.
36. Wolkin A, Angrist B, Wolf AP, Brodie J, Wolkin B, Jaeger J, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology. 1987; 92: 241-246. (Pubitemid 17072904)
37. Wolkin A, Sanfilipo M, Angrist B, Duncan E, Wieland S, Wolf A, et al. Acute d-amphetamine challenge in schozophrenia: effects on cerebral glucose utilization and clinical symptomatology. Psychol Med 1994; 35: 649-657.
38. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, et al. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharm 2008; 33: 279-289. (Pubitemid 350243342)
39. Swerdlow N, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer M, et al. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: Time course studies. Psychopharm (Berl) 2002; 161: 189-201. (Pubitemid 34492664)
40. Lammertsma AA, Hume SP,. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4 (3 Part 1): 153-158.
41. Cohen J,. Statistical Power Analysis for Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc, 1988.
42. Laruelle M, Abi-Dargham A, Van Dyck C, Rosenblatt W, Zea-Ponce Y, Zoghbi S, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995; 36: 1182-1190.
43. Volkow N, Wang G, Fowler J, Logan J, Gatley S, Wong C, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409-415. (Pubitemid 29451617)
44. Drevets W, Gautier C, Price J, Kupfer D, Kinahan P, Grace A, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96. (Pubitemid 32119502)
45. Brauer L, de Wit H,. Subjective responses to D-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psych 1996; 39: 26-31.
46. de Wit H, Uhlenhuth E, Johanson C,. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 1986; 16: 341-360. (Pubitemid 16168232)
47. Gabbay F,. Variations in affect following amphetamine and placebo: Markers of stimulant drug preference. Exp Clin Psychopharmacol 2003; 11: 91-101. (Pubitemid 36237346)
48. Mitchell S, Laurent C, de Wit H,. Interaction of expectancy and the pharmacological effects of D-amphetamine: Subjective effects and self-administration. Psychopharm (Berl) 1996; 125: 371-378. (Pubitemid 26227910)
49. Hutchinson K, Wood M, Swift R,. Personality factors moderate subjective and psychophysiological responses to D-amphetamine in humans. Exp Clin Psychopharmacol 1999; 7: 493-501.
50. White TJ, de Wit H,. Differential subjective effects of D-amphetamine by gender,hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 2002; 73: 729-741. (Pubitemid 35251831)
51. Wagner A, Aizenstein H, Venkatraman M, Fudge J, May J, Mazurkewicz L, et al. Altered reward processing in women recovered from anorexia nervosa. Am J Psych 2007; 164: 1842-1849. (Pubitemid 351739237)
52. Kaye WH, Barbarich NC, Putnam K, Gendall KA, Fernstrom J, Fernstrom M, et al. Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Disord 2003; 33: 257-267. (Pubitemid 36457061)
53. Strober M,. Family-genetic perspectives on anorexia nervosa and bulimia nervosa. In:, Brownell K, Fairburn C, editors. Eating Disorders and Obesity-A Comprehensive Handbook. New York: The Guilford Press, 1995, pp. 212-218.
54. Vitousek K, Manke F,. Personality variables and disorders in anorexia nervosa and bulimia nervosa. J Abnorm Psychol 1994; 103: 137-147. (Pubitemid 24066963)
55. Bassareo V, Di Chiara G,. Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments. Neuroscience 1999; 89: 637-641. (Pubitemid 29070991)
56. Bissada H, Tasca G, Barber A, Bradwejn J,. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psych 2008; 165: 1281-1288.
57. Schultz W,. Predictive reward signal of dopamine neurons. J Neurophysiol 1998; 80: 1-27. (Pubitemid 28326237)
58. Schott B, Muinuzzi L, Krebs R, Elmenhorst D, Lang M, Winz O, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neuroscience 2008; 28: 14311-14319.
59. Zastrow A, Kaiser SS, Stippich C, Walther S, Herzog W, Tchanturia K, Belger A, et al. Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry 2009; 166: 608-616.
60. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999; 21: 694-709.
61. 11C]raclopride study in healthy men. Neuropsychopharmacology. 2002; 27: 1027-1035. (Pubitemid 35447639)
62. Floresco S, Tse M, Ghods-Sharifi S,. Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharm 2008; 33: 1966-1979. (Pubitemid 351832587)